## **AMENDMENTS TO THE CLAIMS**

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

## 1-12. (Cancelled)

13. (Currently Amended) A method for treatment or prevention-of osteoarthritis in a subject, which comprises administering to the subject a therapeutically effective amount of a medicament comprising an agent of the formula

$$\begin{array}{c|c} HO & O & O \\ \hline \\ R^1 & O & \\ \hline \\ R^1 & O & \\ \hline \\ R^1 & I-A \\ \hline \end{array}$$

wherein,

R<sup>1</sup> is hydrogen or halogen;

X is  $-(CH_2)_n$ -;  $-CH(R^2)(CH_2)_n$ -;  $-CH_2O(CH_2)_n$ -;  $-CH_2NH$ -; benzyl;  $-C(R^2)$ = $-CH_2CH(OH)$ -; or thiazol-2,5-diyl;

Y is -S-S-; -(CH<sub>2</sub>)<sub>n</sub>-; -O-; -NH-; -N(R<sup>2</sup>)-; -CH=CH-; -NHC(O)NH-; -N(R<sup>2</sup>)C(O)N(R<sup>2</sup>)-; -N[CH<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(OCH<sub>3</sub>)<sub>2</sub>]-; N(CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>)-; -N(CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>)C(O)N(CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>)-; -N(alkoxyalkyl)-; N(cycloalkyl-methyl); 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen, 1,3-phenylen and 1,4-phenylen, wherein the phenylen groups are optionally substituted by 1-4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxyl, carboxy, -COO-lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid pyrrolidin-l-yl)-2-oxo-ethoxy, N-hydroxycarbamimidoyl, 5-oxo[1,2,4]oxadiazolyl, 2-oxo-[1,2,3,5]oxathiadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and 5-tert-butylsulfanyl-[1,2,4]oxadiazolyl;

- X' is  $-(CH_2)_n$ -;  $-(CH_2)_nCH(R^2)$ -;  $-(CH_2)_nOCH_2$ -;  $-NHCH_2$ -; benzyl,  $-CH=C(R^2)$ -;  $-CH(OH)CH_2$ -; or thiazol-2,5-diyl;
- R<sup>2</sup> is a lower alkyl, lower alkoxy or benzyl; and
- n is 0-3,

or a pharmaceutically acceptable salt or mono- or diester thereof, wherein the agent is capable of inhibiting serum amyloid P component (SAP) ligand binding

activity or depleting SAP from the plasma of the subject.

- 14. (Previously Presented) A method according to claim 13, wherein the agent is capable of being bound by a ligand binding site present on SAP.
- 15. (Previously Presented) A method according to claim 14, wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with SAP and a second protein, wherein at least two of the ligands are the same or different, one of which is capable of being bound by a ligand binding site present on SAP and another is capable of being bound by a ligand binding site present on the second protein.
- 16. (Cancelled)
- 17. (Cancelled)
- 18. (Currently Amended) A method according to claim [[17]] 15, wherein the linker comprises a linear or branched hydrocarbylene in which one or more of the carbon atoms thereof is optionally substituted by a heteroatom.
- 19. (Cancelled)
- 20. (Previously Presented) A method according to claim 15, wherein the second protein is SAP.
- 21. (Cancelled)

- 22. (Cancelled)
- 23. (Cancelled)
- 24. (Cancelled)
- 25. (Cancelled)
- 26. (Currently Amended) A method for treatment or prevention of osteoarthritis in a subject, which comprises administering to the subject a therapeutically effective amount of a medicament comprising (R)-1-[6-(R)-2-Carboxy-pyrrolidin-l-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or mono- or diester thereof.
- 27. (Cancelled)
- 28. (New) The method of claim 13, wherein,
- X is  $-(CH_2)_n$ ;  $-CH(R^2)(CH_2)_n$ ;  $-CH_2O(CH_2)_n$ ; or  $-C(R^2)$ =CH-;
- is -(CH<sub>2</sub>)<sub>n</sub>-; -CH=CH-; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen, 1,3-phenylen and 1,4-phenylen, wherein the phenylen groups are optionally substituted by 1-4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxyl, carboxy, -COO-lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid pyrrolidin-l-yl)-2-oxo-ethoxy, N-hydroxycarbamimidoyl, 5-oxo[1,2,4]oxadiazolyl, 2-oxo-[1,2,3,5]oxathiadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and 5-tert-butylsulfanyl-[1,2,4]oxadiazolyl; and
- X' is  $-(CH_2)_n$ -;  $-(CH_2)_nCH(R^2)$ -;  $-(CH_2)_nOCH_2$ -; or  $-CH=C(R^2)$ -.
- 29. (New) The method of claim 13, wherein,
- X is  $-(CH_2)_n$  or  $-CH(R^2)(CH_2)_n$ -;
- Y is -(CH<sub>2</sub>)<sub>n</sub>-; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen, 1,3-phenylen and 1,4-phenylen; and

$$X'$$
 is  $-(CH_2)_n$ - or  $-(CH_2)_nCH(R^2)$ -.

- 30. (New) The method of claim 13, wherein,
- X is  $-(CH_2)_n$ -;
- Y is  $-(CH_2)_n$ -; and
- X' is  $-(CH_2)_{n}$ -.

00646019